A commercial-stage biopharmaceutical company developing cell and gene therapies for rare diseases.
About
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing cell and gene therapies for serious and life-threatening rare diseases. Their lead product, ZEVASKYN (prademagene zamikeracel), is an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company also has a pipeline of AAV-based gene therapies for ophthalmic and other rare genetic disorders.
Pricing
View pricing page ↗
Tags
Total Employees
229
Current headcount
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Abeona Therapeutics do?
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing cell and gene therapies for serious and life-threatening rare diseases. Their lead product, ZEVASKYN (prademagene zamikeracel), is an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company also has a pipeline of AAV-based gene therapies for ophthalmic and other rare genetic disorders.
Where is Abeona Therapeutics headquartered?
Abeona Therapeutics is headquartered in Cleveland, United States.
When was Abeona Therapeutics founded?
Abeona Therapeutics was founded in 1974.
What industry does Abeona Therapeutics operate in?
Abeona Therapeutics operates in Biotech, Gene Therapy, Rare Diseases.
How many employees does Abeona Therapeutics have?
Abeona Therapeutics has approximately 229 people on record.
Similar Startups